Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas-Reference-Cited by-同舟云学术

Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas

Published:2017-05-28 Issue:2 Volume:87 Page:127-135
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Zhong Xu¹^ORCID,Ye Lei¹²^ORCID,Su TingWei¹,Xie Jing³,Zhou Weiwei¹,Jiang Yiran¹,Jiang Lei¹,Ning Guang¹²,Wang Weiqing¹²

Affiliation:

1. Shanghai Key Laboratory for Endocrine Tumors; Shanghai Clinical Center for Endocrine and Metabolic Diseases; Key Laboratory for Endocrine and Metabolic Diseases of Chinese Health Ministry; Ruijin Hospital; Shanghai Jiao Tong University School of Medicine; Shanghai China

2. Laboratory for Endocrine & Metabolic Diseases of Institute of Health Science; Shanghai Jiao Tong University School of Medicine and Shanghai Institutes for Biological Sciences; Chinese Academy of Sciences; Shanghai China

3. Department of Pathology; Ruijin Hospital; Shanghai Jiao Tong University School of Medicine; Shanghai China

Funder

National International Science Cooperation Foundation

National Natural Science Foundation of China

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cen.13357/fullpdf

Reference29 articles.

1. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators;Ayala-Ramirez;J Clin Endocrinol Metab,2011